Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Fibrogenesis & Tissue Repair
Published in: Fibrogenesis & Tissue Repair 1/2012

Open Access 01-12-2012 | Review

Genomics and proteomics in liver fibrosis and cirrhosis

Authors: Rebekka A Hannivoort, Virginia Hernandez-Gea, Scott L Friedman

Published in: Fibrogenesis & Tissue Repair | Issue 1/2012

Login to get access

Abstract

Genomics and proteomics have become increasingly important in biomedical science in the past decade, as they provide an opportunity for hypothesis-free experiments that can yield major insights not previously foreseen when scientific and clinical questions are based only on hypothesis-driven approaches. Use of these tools, therefore, opens new avenues for uncovering physiological and pathological pathways. Liver fibrosis is a complex disease provoked by a range of chronic injuries to the liver, among which are viral hepatitis, (non-) alcoholic steatohepatitis and autoimmune disorders. Some chronic liver patients will never develop fibrosis or cirrhosis, whereas others rapidly progress towards cirrhosis in a few years. This variety can be caused by disease-related factors (for example, viral genotype) or host-factors (genetic/epigenetic). It is vital to establish accurate tools to identify those patients at highest risk for disease severity or progression in order to determine who are in need of immediate therapies. Moreover, there is an urgent imperative to identify non-invasive markers that can accurately distinguish mild and intermediate stages of fibrosis. Ideally, biomarkers can be used to predict disease progression and treatment response, but these studies will take many years due to the requirement for lengthy follow-up periods to assess outcomes. Current genomic and proteomic research provides many candidate biomarkers, but independent validation of these biomarkers is lacking, and reproducibility is still a key concern. Thus, great opportunities and challenges lie ahead in the field of genomics and proteomics, which, if successful, could transform the diagnosis and treatment of chronic fibrosing liver diseases.
Literature
1.
2.
3.
Juran BD, Lazaridis KN: Applying genomics to the study of complex disease. Semin Liver Dis. 2007, 27: 3-12.PubMedCrossRef
4.
Osterreicher CH, Stickel F, Brenner DA: Genomics of liver fibrosis and cirrhosis. Semin Liver Dis. 2007, 27: 28-43.PubMedCrossRef
5.
Juran BD, Lazaridis KN: Genomics and complex liver disease: Challenges and opportunities. Hepatology. 2006, 44: 1380-90.PubMedCrossRef
6.
Grant A, Neuberger J: Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999, 45 (Suppl 4): IV1-IV11.PubMedCentralPubMed
7.
McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990, 99: 1396-400.PubMed
8.
Piccinino F, Sagnelli E, Pasquale G, Giusti G: Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986, 2: 165-73.PubMedCrossRef
9.
Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002, 97: 2614-8.PubMedCrossRef
10.
Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F: Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol. 2003, 38: 427-32.PubMedCrossRef
11.
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005, 128: 1898-906.PubMedCrossRef
12.
Cox LA, Schlabritz-Loutsevitch N, Hubbard GB, Nijland MJ, McDonald TJ, Nathanielsz PW: Gene expression profile differences in left and right liver lobes from mid-gestation fetal baboons: a cautionary tale. J Physiol. 2006, 572: 59-66.PubMedCentralPubMedCrossRef
13.
Skripenova S, Trainer TD, Krawitt EL, Blaszyk H: Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol. 2007, 60: 321-4.PubMedCentralPubMedCrossRef
14.
Bedossa P, Dargere D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003, 38: 1449-57.PubMedCrossRef
15.
Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L: Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci. 2003, 73: 386-402.PubMedCrossRef
16.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003, 38: 518-26.PubMedCrossRef
17.
Martinez SM, Crespo G, Navasa M, Forns X: Noninvasive assessment of liver fibrosis. Hepatology. 2011, 53: 325-35.PubMedCrossRef
18.
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001, 357: 1069-75.PubMedCrossRef
19.
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004, 3: 8.PubMedCentralPubMedCrossRef
20.
Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol. 2002, 1: 3.PubMedCentralPubMedCrossRef
21.
Smith JO, Sterling RK: Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009, 30: 557-76.PubMedCrossRef
22.
23.
Shaheen AA, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007, 102: 2589-600.PubMedCrossRef
24.
Trinchet JC, Hartmann DJ, Pateron D, Laarif M, Callard P, Ville G, Beaugrand M: Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol. 1991, 12: 139-44.PubMedCrossRef
25.
Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet. 1993, 342: 895-8.PubMedCrossRef
26.
Gallorini A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A: Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver. 1994, 14: 257-64.PubMedCrossRef
27.
Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol. 1994, 29: 474-9.PubMedCrossRef
28.
Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999, 44: 624-30.PubMedCrossRef
29.
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002, 316: 71-81.PubMedCrossRef
30.
Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H: The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009, 16: 418-29.PubMedCrossRef
31.
Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-Bismut F, Poynard T: Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007, 26: 847-58.PubMedCrossRef
32.
Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007, 381: 107-13.PubMedCrossRef
33.
Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A: New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol. 2006, 12: 7604-12.PubMedCentralPubMed
34.
Mas VR, Fisher RA, Archer KJ, Maluf DG: Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics. 2009, 6: 421-31.PubMedCrossRef
35.
Kuramitsu Y, Nakamura K: Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics. 2005, 2: 589-601.PubMedCrossRef
36.
Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002, 1: 304-13.PubMedCrossRef
37.
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE: Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics. 2004, 3: 960-9.PubMedCrossRef
38.
Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999, 23: 41-6.PubMedCrossRef
39.
Sellick GS, Longman C, Tolmie J, Newbury-Ecob R, Geenhalgh L, Hughes S, Whiteford M, Garrett C, Houlston RS: Genomewide linkage searches for Mendelian disease loci can be efficiently conducted using high-density SNP genotyping arrays. Nucleic Acids Res. 2004, 32: e164.PubMedCentralPubMedCrossRef
40.
Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipshutz R, Chee M, Lander ES: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998, 280: 1077-82.PubMedCrossRef
41.
Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD: Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 2003, 302: 2141-4.PubMedCrossRef
42.
Yamamoto M, Wakatsuki T, Hada A, Ryo A: Use of serial analysis of gene expression (SAGE) technology. J Immunol Methods. 2001, 250: 45-66.PubMedCrossRef
43.
Ruijter JM, Van Kampen AH, Baas F: Statistical evaluation of SAGE libraries: consequences for experimental design. Physiol Genomics. 2002, 11: 37-44.PubMedCrossRef
44.
45.
Capelo JL, Carreira R, Diniz M, Fernandes L, Galesio M, Lodeiro C, Santos HM, Vale G: Overview on modern approaches to speed up protein identification workflows relying on enzymatic cleavage and mass spectrometry-based techniques. Anal Chim Acta. 2009, 650: 151-9.PubMedCrossRef
46.
Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M: Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001, 1: 377-96.PubMedCrossRef
47.
Unlu M, Morgan ME, Minden JS: Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997, 18: 2071-7.PubMedCrossRef
48.
Schwartz JC, Senko MW, Syka JE: A two-dimensional quadrupole ion trap mass spectrometer. J Am Soc Mass Spectrom. 2002, 13: 659-69.PubMedCrossRef
49.
Marshall AG, Hendrickson CL, Jackson GS: Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom Rev. 1998, 17: 1-35.PubMedCrossRef
50.
Hardman M, Makarov AA: Interfacing the orbitrap mass analyzer to an electrospray ion source. Anal Chem. 2003, 75: 1699-705.PubMedCrossRef
51.
Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Graham Cooks R: The Orbitrap: a new mass spectrometer. J Mass Spectrom. 2005, 40: 430-43.PubMedCrossRef
52.
Hutchens TA: Automaticity and reading in learning-disabled college students. Ann N Y Acad Sci. 1993, 682: 357-8.PubMedCrossRef
53.
Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun. 2002, 292: 587-92.PubMedCrossRef
54.
De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, Merville MP, Fillet M: Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol. 2010, 2010: 906082.PubMedCentralPubMedCrossRef
55.
56.
MacBeath G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science. 2000, 289: 1760-3.PubMed
57.
Low TY, Leow CK, Salto-Tellez M, Chung MC: A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics. 2004, 4: 3960-74.PubMedCrossRef
58.
Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stuhler K, Graf J, Roeb E: Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics. 2006, 6: 6538-48.PubMedCrossRef
59.
60.
Andringa KK, King AL, Eccleston HB, Mantena SK, Landar A, Jhala NC, Dickinson DA, Squadrito GL, Bailey SM: Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. Am J Physiol Gastrointest Liver Physiol. 2010, 298: G732-45.PubMedCentralPubMedCrossRef
61.
Kharbanda KK, Vigneswara V, McVicker BL, Newlaczyl AU, Bailey K, Tuma D, Ray DE, Carter WG: Proteomics reveal a concerted upregulation of methionine metabolic pathway enzymes, and downregulation of carbonic anhydrase-III, in betaine supplemented ethanol-fed rats. Biochem Biophys Res Commun. 2009, 381: 523-7.PubMedCentralPubMedCrossRef
62.
Liu EH, Chen MF, Yeh TS, Ho YP, Wu RC, Chen TC, Jan YY, Pan TL: A useful model to audit liver resolution from cirrhosis in rats using functional proteomics. J Surg Res. 2007, 138: 214-23.PubMedCrossRef
63.
Kirpich IA, Gobejishvili LN, Bon Homme M, Waigel S, Cave M, Arteel G, Barve SS, McClain CJ, Deaciuc IV: Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem. 2011, 22: 38-45.PubMedCrossRef
64.
Zhang X, Yang J, Guo Y, Ye H, Yu C, Xu C, Xu L, Wu S, Sun W, Wei H, Gao X, Zhu Y, Qian X, Jiang Y, Li Y, He F: Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology. 2010, 51: 1190-9.PubMedCrossRef
65.
Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, Seki S, Kuroki T, Yoshizato K: Proteome analysis of rat hepatic stellate cells. Hepatology. 2000, 32: 268-77.PubMedCrossRef
66.
Kawada N, Kristensen DB, Asahina K, Nakatani K, Minamiyama Y, Seki S, Yoshizato K: Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem. 2001, 276: 25318-23.PubMedCrossRef
67.
Deng X, Liang J, Lin ZX, Wu FS, Zhang YP, Zhang ZW: Natural taurine promotes apoptosis of human hepatic stellate cells in proteomics analysis. World J Gastroenterol. 2010, 16: 1916-23.PubMedCentralPubMedCrossRef
68.
Yokoyama Y, Terai S, Ishikawa T, Aoyama K, Urata Y, Marumoto Y, Nishina H, Nakamura K, Okita K, Sakaida I: Proteomic analysis of serum marker proteins in recipient mice with liver cirrhosis after bone marrow cell transplantation. Proteomics. 2006, 6: 2564-70.PubMedCrossRef
69.
Shimada T, Nakanishi T, Toyama A, Yamauchi S, Kanzaki A, Fujiwake H, Sato TA, Ikegawa M: Potential implications for monitoring serum bile acid profiles in circulation with serum proteome for carbon tetrachloride-induced liver injury/regeneration model in mice. J Proteome Res. 2010, 9: 4490-500.PubMedCrossRef
70.
Smyth R, Lane CS, Ashiq R, Turton JA, Clarke CJ, Dare TO, York MJ, Griffiths W, Munday MR: Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol Toxicol. 2009, 25: 499-512.PubMedCrossRef
71.
Walters KA, Katze MG: Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?. Antiviral Res. 2009, 81: 198-208.PubMedCentralPubMedCrossRef
72.
Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, Larson AM, Yeh MM, Camp DG, Smith RD, Katze MG: Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology. 2007, 46: 649-57.PubMedCrossRef
73.
Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stuhler K: Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009, 49: 1257-66.PubMedCentralPubMedCrossRef
74.
White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P, Gattu M, Rockey DC, Berrey MM, McHutchison JG: Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med. 2007, 5: 33.PubMedCentralPubMedCrossRef
75.
Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID: Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology. 2010, 138: 1123-33. e1-3PubMedCrossRef
76.
Gangadharan B, Antrobus R, Dwek RA, Zitzmann N: Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem. 2007, 53: 1792-9.PubMedCrossRef
77.
Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S: Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS. 2008, 22: 1433-9.PubMedCentralPubMedCrossRef
78.
Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L, Gourley GR: Novel biomarker candidates to predict hepatic fibrosis in hepatitis c identified by serum proteomics. Dig Dis Sci. 2011, 56: 3305-15.PubMedCentralPubMedCrossRef
79.
Corradi F, Piscaglia F, Flori S, D'Errico-Grigioni A, Vasuri F, Tame MR, Andreone P, Boni P, Gianstefani A, Bolondi L: Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis. 2009, 41: 217-25.PubMedCrossRef
80.
Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H: Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol. 2010, 22: 1066-73.PubMedCrossRef
81.
Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ, Layden TJ, Wright TL, White T, Cheung RC: A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007, 46: 297-306.PubMedCrossRef
82.
Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, Palu G, Alberti A: A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009, 50: 1038-44.PubMedCrossRef
83.
Pradat P, Trepo E, Potthoff A, Bakshi R, Young B, Trepo C, Lagier R, Moreno C, Lemmers A, Gustot T, Degre D, Adler M, Wedemeyer H: The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2010, 51: 356-7.PubMedCrossRef
84.
Narayan R, Gangadharan B, Hantz O, Antrobus R, Garcia A, Dwek RA, Zitzmann N: Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res. 2009, 8: 118-22.PubMedCrossRef
85.
Dienstag JL, McHutchison JG: American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006, 130: 225-30.PubMedCrossRef
86.
Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, Boyer N, Martinot-Peignoux M, Valla D, Vidaud M, Marcellin P: Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008, 57: 516-24.PubMedCrossRef
87.
Hayashida K, Daiba A, Sakai A, Tanaka T, Kaji K, Inaba N, Ando S, Kajiyama N, Terasaki H, Abe A, Ogasawara M, Kohara M, Harada M, Okanoue T, Ito S, Kaneko S: Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2005, 3: 1253-9.PubMedCrossRef
88.
Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW: Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology. 2007, 46: 1548-63.PubMedCentralPubMedCrossRef
89.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009, 41: 1100-4.PubMedCrossRef
90.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009, 41: 1105-9.PubMedCrossRef
91.
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG: Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010, 139: 1181-9.PubMedCentralPubMedCrossRef
92.
Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH: Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 2008, 105: 7034-9.PubMedCentralPubMedCrossRef
93.
Devitt EJ, Power KA, Lawless MW, Browne JA, Gaora PO, Gallagher WM, Crowe J: Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon alpha-2b and ribavirin. Eur J Gastroenterol Hepatol. 2011, 23: 177-83.PubMedCrossRef
94.
Sun W, Zhong F, Zhi L, Zhou G, He F: Systematic -omics analysis of HBV-associated liver diseases. Cancer Lett. 2009, 286: 89-95.PubMedCrossRef
95.
Zhang L, Peng X, Zhang Z, Feng Y, Jia X, Shi Y, Yang H, Zhang X, Liu L, Yin L, Yuan Z: Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem. 2010, 110: 219-28.PubMed
96.
Lu Y, Liu J, Lin C, Wang H, Jiang Y, Wang J, Yang P, He F: Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. BMC Gastroenterol. 2010, 10: 115.PubMedCentralPubMedCrossRef
97.
Marrocco C, Rinalducci S, Mohamadkhani A, D'Amici GM, Zolla L: Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach. Blood Transfus. 2010, 8 (Suppl 3): s105-12.PubMedCentralPubMed
98.
Mohamadkhani A, Jazii FR, Sayehmiri K, Jafari-Nejad S, Montaser-Kouhsari L, Poustchi H, Montazeri G: Plasma myeloperoxidase activity and apolipoprotein A-1 expression in chronic hepatitis B patients. Arch Iran Med. 2011, 14: 254-8.PubMed
99.
Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ: Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005, 51: 328-35.PubMedCrossRef
100.
Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003, 39: 222-30.PubMedCrossRef
101.
Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, Wei L: Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Proteomics. 2009, 9: 1672-82.PubMedCrossRef
102.
Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS: Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol. 2006, 45: 306-20.PubMedCrossRef
103.
Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V: A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005, 42: 665-74.PubMedCrossRef
104.
Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N: Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010, 51: 111-20.PubMedCentralPubMedCrossRef
105.
Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E: Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol. 2009, 44: 1471-6.PubMedCrossRef
106.
Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, Younossi ZM: A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology. 2007, 46: 166-72.PubMedCrossRef
107.
Wilfred de Alwis NM, Day CP: Genes and nonalcoholic fatty liver disease. Curr Diab Rep. 2008, 8: 156-63.PubMedCrossRef
108.
Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009, 9: 271.PubMedCentralPubMedCrossRef
109.
Charlton M: Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol. 2007, 102: 409-11.PubMedCrossRef
110.
111.
Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW: Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut. 2001, 49: 565-76.PubMedCentralPubMedCrossRef
112.
Li YZ, Hu CJ, Leng XM, Zhao GF, Li N, Xu Y: Promising diagnostic biomarkers for primary biliary cirrhosis identified with magnetic beads and MALDI-TOF-MS. Anat Rec (Hoboken). 2009, 292: 455-60.CrossRef
113.
Tahiri F, Le Naour F, Huguet S, Lai-Kuen R, Samuel D, Johanet C, Saubamea B, Tricottet V, Duclos-Vallee JC, Ballot E: Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology. 2008, 47: 937-48.PubMedCrossRef
114.
Song H, Sokolov M: Analysis of protein expression and compartmentalization in retinal neurons using serial tangential sectioning of the retina. J Proteome Res. 2009, 8: 346-51.PubMedCrossRef
115.
Bowlus CL, Seeley EH, Roder J, Grigorieva J, Roder H, Caprioli RM, Gershwin M: In situ mass spectrometry of autoimmune liver diseases. Cell Mol Immunol. 2011, 8: 237-42.PubMedCentralPubMedCrossRef
116.
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007, 27: 55-76.PubMedCrossRef
117.
Makridakis M, Vlahou A: Secretome proteomics for discovery of cancer biomarkers. J Proteomics. 2010, 73: 2291-305.PubMedCrossRef
118.
Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, Liu F, You XF, Han YX, Zhao ZY, Cen S, Li JR, Song DQ, Jiang JD: Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology. 2010, 52: 845-53.PubMedCrossRef
Metadata
Title
Genomics and proteomics in liver fibrosis and cirrhosis
Authors
Rebekka A Hannivoort
Virginia Hernandez-Gea
Scott L Friedman
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue 1/2012
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-5-1

Other articles of this Issue 1/2012

Fibrogenesis & Tissue Repair 1/2012 Go to the issue

Research

Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis

Review

Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis

Review

Molecular and cellular mechanisms of pulmonary fibrosis

Review

Augmenter of liver regeneration

Review

Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target

Research

Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits